Advertisement

Topics

Amgen's supplemental NDA for data on Kyprolis label accepted for FDA review

04:56 EDT 31 Aug 2017 | SmartBrief

Amgen's supplemental new drug application for additional survival data from a late-stage trial on the label of Kyprolis, or c -More

Original Article: Amgen's supplemental NDA for data on Kyprolis label accepted for FDA review

NEXT ARTICLE

More From BioPortfolio on "Amgen's supplemental NDA for data on Kyprolis label accepted for FDA review"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...